当前位置： SCI文献检索 > PHARMACOECONOMICS期刊下所有文献 > Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Abstract：

:About one-quarter of men aged 50 years and older experience voiding problems due to benign prostatic hyperplasia (BPH). Until about 10 years ago, surgery (particularly transurethral resection of the prostate) was the only effective treatment for symptomatic BPH. Over the last decade, several new treatments have been introduced. These include different types of medication (alpha-blockers and finasteride), thermotherapy, laser prostatectomy, needle ablation and vaporisation methods. The diffusion of these less invasive treatment modalities has resulted not only in a decrease in the age-adjusted surgery rates, but also in an increase of the total number of men treated for BPH. A large number of studies on clinical benefits and risks reveal that the conventional types of surgery remain the most effective treatments, whereas new interventional therapies require a shorter hospital stay and result in fewer short term complications. The efficacy of medication is lower than that of interventional treatments. Adverse effects include dizziness and orthostatic hypotension (alpha-blockers) and decreased sexual function (finasteride), but are generally mild. There is some evidence that medication and minimally invasive treatments may preclude eventual surgical treatment, but the precise effect is difficult to estimate because of differences in the study populations and the relatively short study periods. As a result of the dynamic nature of BPH treatment and the lack of long term data, the cost effects of the introduction of the various new treatments are also difficult to assess. Given the aging of the population and the growing percentage of patients with BPH for whom any type of treatment can be considered, a considerable increase of total costs can be expected. Long term prospective studies are necessary to gain insight into the most cost-effective treatment for different patient groups.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Stoevelaar HJ,McDonnell J

doi

10.2165/00019053-200119020-00003

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

131-53

issue

eissn

1170-7690

issn

1179-2027

journal_volume

pub_type

杂志文章,评审

在线工具

Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.